Forbion catering to abundance of maturing European biotechs with new growth fund

Forbion’s launch of a new late-stage and crossover fund reflects the growing need for capital among maturing European biotechs, including those that are past the proof-of-concept stage and are seeking liquidity.

Over the past few years, most European life sciences VCs have been raising bigger early-stage funds that have poured larger amounts of cash into start-ups. Companies in that category are now coming of age: some have assets in later-stage trials, some are seeking mezzanine rounds ahead of planned IPOs, and some public companies are looking to take next steps such as dual listings...